{"filing":{"accession_number":"0001493152-26-035999","cik":"0000908259","ticker":"OTLC","company_name":"Oncotelic Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-03","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226035999/form8-k.htm"},"events":[{"id":23981,"run_id":21693,"accession_number":"0001493152-26-035999","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Oncotelic Therapeutics entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP on August 3, 2026, issuing a convertible promissory note of $178,410 principal amount convertible into common stock at $0.06 per share, plus 500,000 commitment shares. This unregistered private placement combines convertible debt and equity commitment shares that will dilute existing shareholders upon conversion and exercise.","company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24348,"accession_number":"0001493152-26-035999","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Oncotelic entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP on August 3, 2026, issuing a convertible promissory note of $178,410 principal amount convertible into common stock at $0.06 per share, plus 500,000 commitment shares. This is a classic dilutive private placement with convertible debt and equity commitment shares that will dilute existing shareholders upon conversion and exercise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:35:29.644901+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24349,"accession_number":"0001493152-26-035999","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.03 is the dedicated 8-K Item for creation of direct financial obligations, typically debt issuances, credit facilities, or term loans. The section heading explicitly references \"Creation of a Direct Financial Obligation,\" which is the hallmark of debt_issuance classification. Without the full text, the Item number and heading strongly indicate a debt or credit arrangement has been entered into.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:35:29.644901+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24351,"accession_number":"0001493152-26-035999","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 explicitly addresses \"Unregistered Sale of Equity Securities,\" which is the defining characteristic of a dilutive issuance. The filing discloses an unregistered equity sale by Oncotelic Therapeutics, a small-cap biotech company, which is material to investors as it affects share dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:35:29.644901+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24348,"accession_number":"0001493152-26-035999","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Oncotelic entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP on August 3, 2026, issuing a convertible promissory note of $178,410 principal amount convertible into common stock at $0.06 per share, plus 500,000 commitment shares. This is a classic dilutive private placement with convertible debt and equity commitment shares that will dilute existing shareholders upon conversion and exercise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:35:29.644901+00:00","company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","filing_date":"2026-08-04"},{"id":24349,"accession_number":"0001493152-26-035999","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.03 is the dedicated 8-K Item for creation of direct financial obligations, typically debt issuances, credit facilities, or term loans. The section heading explicitly references \"Creation of a Direct Financial Obligation,\" which is the hallmark of debt_issuance classification. Without the full text, the Item number and heading strongly indicate a debt or credit arrangement has been entered into.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:35:29.644901+00:00","company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","filing_date":"2026-08-04"},{"id":24351,"accession_number":"0001493152-26-035999","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 explicitly addresses \"Unregistered Sale of Equity Securities,\" which is the defining characteristic of a dilutive issuance. The filing discloses an unregistered equity sale by Oncotelic Therapeutics, a small-cap biotech company, which is material to investors as it affects share dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:35:29.644901+00:00","company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","filing_date":"2026-08-04"}]}